- Home
- BCG vs RNTX Comparison
BCG vs RNTX Comparison
Compare BCG & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCG
- RNTX
- Stock Information
- Founded
- BCG 2016
- RNTX 2001
- Country
- BCG United States
- RNTX United States
- Employees
- BCG N/A
- RNTX N/A
- Industry
- BCG
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- BCG
- RNTX Health Care
- Exchange
- BCG Nasdaq
- RNTX Nasdaq
- Market Cap
- BCG 42.3M
- RNTX 44.2M
- IPO Year
- BCG N/A
- RNTX N/A
- Fundamental
- Price
- BCG $2.01
- RNTX $1.75
- Analyst Decision
- BCG
- RNTX
- Analyst Count
- BCG 0
- RNTX 0
- Target Price
- BCG N/A
- RNTX N/A
- AVG Volume (30 Days)
- BCG 64.3K
- RNTX 27.6K
- Earning Date
- BCG 05-26-2025
- RNTX 05-14-2025
- Dividend Yield
- BCG N/A
- RNTX N/A
- EPS Growth
- BCG N/A
- RNTX N/A
- EPS
- BCG N/A
- RNTX N/A
- Revenue
- BCG $164,877,000.00
- RNTX N/A
- Revenue This Year
- BCG N/A
- RNTX N/A
- Revenue Next Year
- BCG N/A
- RNTX N/A
- P/E Ratio
- BCG N/A
- RNTX N/A
- Revenue Growth
- BCG 1.25
- RNTX N/A
- 52 Week Low
- BCG $1.71
- RNTX $1.61
- 52 Week High
- BCG $12.22
- RNTX $7.42
- Technical
- Relative Strength Index (RSI)
- BCG N/A
- RNTX N/A
- Support Level
- BCG N/A
- RNTX N/A
- Resistance Level
- BCG N/A
- RNTX N/A
- Average True Range (ATR)
- BCG 0.00
- RNTX 0.00
- MACD
- BCG 0.00
- RNTX 0.00
- Stochastic Oscillator
- BCG 0.00
- RNTX 0.00
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03, LTI-01, and others.